JP2016163571A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016163571A5 JP2016163571A5 JP2016039171A JP2016039171A JP2016163571A5 JP 2016163571 A5 JP2016163571 A5 JP 2016163571A5 JP 2016039171 A JP2016039171 A JP 2016039171A JP 2016039171 A JP2016039171 A JP 2016039171A JP 2016163571 A5 JP2016163571 A5 JP 2016163571A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- galactosidase
- specific pharmacological
- pharmacological chaperone
- gala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 102100026277 Alpha-galactosidase A Human genes 0.000 claims 4
- 108010006519 Molecular Chaperones Proteins 0.000 claims 4
- 108010030291 alpha-Galactosidase Proteins 0.000 claims 4
- 230000000144 pharmacologic effect Effects 0.000 claims 4
- 102200077160 rs797044774 Human genes 0.000 claims 3
- 102220486257 Serine hydroxymethyltransferase, cytosolic_N320I_mutation Human genes 0.000 claims 2
- LXBIFEVIBLOUGU-DPYQTVNSSA-N migalastat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O LXBIFEVIBLOUGU-DPYQTVNSSA-N 0.000 claims 2
- 229950007469 migalastat Drugs 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 102220152464 rs144140791 Human genes 0.000 claims 2
- 102220085241 rs879253808 Human genes 0.000 claims 2
- 102220480233 Adhesion G-protein coupled receptor D1_P293A_mutation Human genes 0.000 claims 1
- 102220486386 Alpha-galactosidase A_A288D_mutation Human genes 0.000 claims 1
- 102220486228 Alpha-galactosidase A_G35R_mutation Human genes 0.000 claims 1
- 102220486653 Alpha-galactosidase A_I242N_mutation Human genes 0.000 claims 1
- 102220486151 Alpha-galactosidase A_M72V_mutation Human genes 0.000 claims 1
- 102220486311 Alpha-galactosidase A_P265R_mutation Human genes 0.000 claims 1
- 102220486351 Alpha-galactosidase A_Q280H_mutation Human genes 0.000 claims 1
- 102220486115 Alpha-galactosidase A_R49L_mutation Human genes 0.000 claims 1
- 102220486129 Alpha-galactosidase A_R49S_mutation Human genes 0.000 claims 1
- 102220481462 Alpha-galactosidase A_V316E_mutation Human genes 0.000 claims 1
- 102220486015 Alpha-galactosidase A_W95S_mutation Human genes 0.000 claims 1
- 102220466993 Annexin A3_I219N_mutation Human genes 0.000 claims 1
- 208000024720 Fabry Disease Diseases 0.000 claims 1
- 102220514548 Somatostatin receptor type 1_N34K_mutation Human genes 0.000 claims 1
- 102200076863 c.119C>T Human genes 0.000 claims 1
- 102200076464 c.272T>C Human genes 0.000 claims 1
- 102220362014 c.702C>G Human genes 0.000 claims 1
- 102200077268 c.826A>G Human genes 0.000 claims 1
- 102200077291 c.893A>G Human genes 0.000 claims 1
- 102200076847 c.95T>C Human genes 0.000 claims 1
- 102200077287 rs104894830 Human genes 0.000 claims 1
- 102200076873 rs104894831 Human genes 0.000 claims 1
- 102200077288 rs104894846 Human genes 0.000 claims 1
- 102200076840 rs104894847 Human genes 0.000 claims 1
- 102200065199 rs1057515579 Human genes 0.000 claims 1
- 102200076919 rs1057521047 Human genes 0.000 claims 1
- 102200010382 rs1057521062 Human genes 0.000 claims 1
- 102200077177 rs111422676 Human genes 0.000 claims 1
- 102200076472 rs113173389 Human genes 0.000 claims 1
- 102200069129 rs121434329 Human genes 0.000 claims 1
- 102200005231 rs121908280 Human genes 0.000 claims 1
- 102200023312 rs121912940 Human genes 0.000 claims 1
- 102200158224 rs121918530 Human genes 0.000 claims 1
- 102200063052 rs137852853 Human genes 0.000 claims 1
- 102200077273 rs140329381 Human genes 0.000 claims 1
- 102220104213 rs140506267 Human genes 0.000 claims 1
- 102220141945 rs140804035 Human genes 0.000 claims 1
- 102200036676 rs143947056 Human genes 0.000 claims 1
- 102220260525 rs1554097567 Human genes 0.000 claims 1
- 102200049940 rs1554402092 Human genes 0.000 claims 1
- 102200070822 rs1555710077 Human genes 0.000 claims 1
- 102200077127 rs1555984869 Human genes 0.000 claims 1
- 102200094055 rs17576 Human genes 0.000 claims 1
- 102200077342 rs190347120 Human genes 0.000 claims 1
- 102220228444 rs200183599 Human genes 0.000 claims 1
- 102220007476 rs267606804 Human genes 0.000 claims 1
- 102200077267 rs28935485 Human genes 0.000 claims 1
- 102220087827 rs28935489 Human genes 0.000 claims 1
- 102220082624 rs370063423 Human genes 0.000 claims 1
- 102200078669 rs370595480 Human genes 0.000 claims 1
- 102220214294 rs373488862 Human genes 0.000 claims 1
- 102200013203 rs387906468 Human genes 0.000 claims 1
- 102200129586 rs397514731 Human genes 0.000 claims 1
- 102200018556 rs587779420 Human genes 0.000 claims 1
- 102200020122 rs6054 Human genes 0.000 claims 1
- 102200076593 rs727503948 Human genes 0.000 claims 1
- 102200077186 rs727504348 Human genes 0.000 claims 1
- 102220038571 rs72937434 Human genes 0.000 claims 1
- 102200077248 rs730880451 Human genes 0.000 claims 1
- 102220277657 rs746045584 Human genes 0.000 claims 1
- 102200007201 rs750496798 Human genes 0.000 claims 1
- 102200068463 rs760106433 Human genes 0.000 claims 1
- 102200065197 rs760277934 Human genes 0.000 claims 1
- 102220064075 rs762381137 Human genes 0.000 claims 1
- 102220114730 rs763889166 Human genes 0.000 claims 1
- 102220166398 rs766522793 Human genes 0.000 claims 1
- 102220200219 rs770497192 Human genes 0.000 claims 1
- 102220272713 rs777653224 Human genes 0.000 claims 1
- 102200076503 rs782197638 Human genes 0.000 claims 1
- 102220075588 rs796053298 Human genes 0.000 claims 1
- 102220055601 rs797044497 Human genes 0.000 claims 1
- 102200160956 rs869320708 Human genes 0.000 claims 1
- 102200136953 rs879253837 Human genes 0.000 claims 1
- 102200037543 rs879254797 Human genes 0.000 claims 1
- 102220456815 rs886051894 Human genes 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2814108P | 2008-02-12 | 2008-02-12 | |
| US61/028,141 | 2008-02-12 | ||
| US3568408P | 2008-03-11 | 2008-03-11 | |
| US61/035,684 | 2008-03-11 | ||
| US9363108P | 2008-09-02 | 2008-09-02 | |
| US61/093,631 | 2008-09-02 | ||
| US11349608P | 2008-11-11 | 2008-11-11 | |
| US61/113,496 | 2008-11-11 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014244283A Division JP2015091239A (ja) | 2008-02-12 | 2014-12-02 | 疾病の薬理シャペロン治療に対する応答性を予測する方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018245609A Division JP6837469B2 (ja) | 2008-02-12 | 2018-12-27 | 疾病の薬理シャペロン治療に対する応答性を予測する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016163571A JP2016163571A (ja) | 2016-09-08 |
| JP2016163571A5 true JP2016163571A5 (enExample) | 2016-12-01 |
| JP6672013B2 JP6672013B2 (ja) | 2020-03-25 |
Family
ID=40957500
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010546901A Active JP5844045B2 (ja) | 2008-02-12 | 2009-02-12 | 疾病の薬理シャペロン治療に対する応答性を予測する方法 |
| JP2014244283A Pending JP2015091239A (ja) | 2008-02-12 | 2014-12-02 | 疾病の薬理シャペロン治療に対する応答性を予測する方法 |
| JP2016039171A Active JP6672013B2 (ja) | 2008-02-12 | 2016-03-01 | 疾病の薬理シャペロン治療に対する応答性を予測する方法 |
| JP2018245609A Active JP6837469B2 (ja) | 2008-02-12 | 2018-12-27 | 疾病の薬理シャペロン治療に対する応答性を予測する方法 |
| JP2021019383A Active JP7277493B2 (ja) | 2008-02-12 | 2021-02-09 | 疾病の薬理シャペロン治療に対する応答性を予測する方法 |
| JP2023076515A Withdrawn JP2023109807A (ja) | 2008-02-12 | 2023-05-08 | 疾病の薬理シャペロン治療に対する応答性を予測する方法 |
| JP2025097940A Pending JP2025148351A (ja) | 2008-02-12 | 2025-06-11 | 疾病の薬理シャペロン治療に対する応答性を予測する方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010546901A Active JP5844045B2 (ja) | 2008-02-12 | 2009-02-12 | 疾病の薬理シャペロン治療に対する応答性を予測する方法 |
| JP2014244283A Pending JP2015091239A (ja) | 2008-02-12 | 2014-12-02 | 疾病の薬理シャペロン治療に対する応答性を予測する方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018245609A Active JP6837469B2 (ja) | 2008-02-12 | 2018-12-27 | 疾病の薬理シャペロン治療に対する応答性を予測する方法 |
| JP2021019383A Active JP7277493B2 (ja) | 2008-02-12 | 2021-02-09 | 疾病の薬理シャペロン治療に対する応答性を予測する方法 |
| JP2023076515A Withdrawn JP2023109807A (ja) | 2008-02-12 | 2023-05-08 | 疾病の薬理シャペロン治療に対する応答性を予測する方法 |
| JP2025097940A Pending JP2025148351A (ja) | 2008-02-12 | 2025-06-11 | 疾病の薬理シャペロン治療に対する応答性を予測する方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (8) | US8592362B2 (enExample) |
| EP (4) | EP2252313B1 (enExample) |
| JP (7) | JP5844045B2 (enExample) |
| AU (7) | AU2009214648B2 (enExample) |
| CA (1) | CA2715407C (enExample) |
| CY (3) | CY1116466T1 (enExample) |
| DK (3) | DK3470077T3 (enExample) |
| ES (3) | ES2541933T3 (enExample) |
| HR (3) | HRP20150728T1 (enExample) |
| HU (3) | HUE026543T2 (enExample) |
| LT (2) | LT3470077T (enExample) |
| MX (1) | MX2010008835A (enExample) |
| PL (3) | PL3470077T3 (enExample) |
| PT (3) | PT2946785T (enExample) |
| SI (3) | SI3470077T1 (enExample) |
| WO (1) | WO2009102895A2 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2652553C (en) | 2006-05-16 | 2020-08-18 | Amicus Therapeutics, Inc. | Use of 1-deoxygalactonojirimycin or a salt thereof in the treatment of fabry disease |
| LT3470077T (lt) | 2008-02-12 | 2021-02-25 | Amicus Therapeutics, Inc. | Atsako į ligų gydymą farmakologiniu šaperonu prognozavimo būdas |
| AU2009223125A1 (en) * | 2008-03-12 | 2009-09-17 | Amicus Therapeutics, Inc. | Assays for diagnosing and evaluating treatment options for Pompe disease |
| AR078498A1 (es) * | 2009-10-01 | 2011-11-09 | Baylor Res Inst | Tratamiento de calvicie de patron masculino por induccion local del defecto metabolico de la enfermedad de fabry |
| US20120283290A1 (en) * | 2011-05-06 | 2012-11-08 | Amicus Therapeutics Inc. | Quantitation of gl3 in urine |
| SG10202003753PA (en) | 2014-09-30 | 2020-05-28 | Amicus Therapeutics Inc | Highly potent acid alpha-glucosidase with enhanced carbohydrates |
| AU2016233135B2 (en) | 2015-03-19 | 2021-07-08 | Translate Bio, Inc. | mRNA therapy for pompe disease |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| CA3010205A1 (en) | 2015-12-30 | 2017-07-06 | Amicus Therapeutics, Inc. | Augmented acid alpha-glucosidase for the treatment of pompe disease |
| SMT202100452T1 (it) | 2015-12-30 | 2021-09-14 | Amicus Therapeutics Inc | Alfa-glucosidasi acida potenziata per il trattamento della malattia di pompe |
| KR20190087673A (ko) | 2016-03-22 | 2019-07-24 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Ｇｌａ 유전자에 ｇ9331ａ 돌연변이를 갖는 환자에서 파브리 질병의 치료 방법 |
| CN109475607B (zh) | 2016-03-30 | 2022-04-26 | 阿米库斯治疗学公司 | 包含重组酸性α-葡糖苷酶的配制品 |
| KR20250017756A (ko) | 2016-03-30 | 2025-02-04 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 재조합 산 알파-글루코시다제를 포함하는 제형 |
| SG11201808592PA (en) * | 2016-03-30 | 2018-10-30 | Amicus Therapeutics Inc | Method for selection of high m6p recombinant proteins |
| EP4378524A3 (en) | 2016-07-19 | 2024-08-14 | Amicus Therapeutics, Inc. | Treatment of fabry disease in ert-naive and ert-experienced patients |
| JP6546135B2 (ja) | 2016-08-24 | 2019-07-17 | 株式会社ノリタケカンパニーリミテド | 積層造形焼成体、積層造形焼成体の製造方法および積層造形焼成体製造用キット |
| ES3047063T3 (en) * | 2016-10-20 | 2025-12-03 | Sangamo Therapeutics Inc | Methods and compositions for the treatment of fabry disease |
| EA039750B1 (ru) * | 2017-03-30 | 2022-03-10 | Амикус Терапьютикс, Инк. | Способ отбора рекомбинантных белков с высоким содержанием m6p |
| EP4223310A3 (en) | 2017-05-15 | 2023-10-11 | Amicus Therapeutics, Inc. | Recombinant human acid alpha-glucosidase |
| TW202322814A (zh) | 2017-05-30 | 2023-06-16 | 美商阿米庫斯醫療股份有限公司 | 治療有腎損傷的法布里患者的方法 |
| WO2018222655A1 (en) | 2017-05-30 | 2018-12-06 | Amicus Therapeutics, Inc. | Methods of treating fabry patients having renal impairment |
| WO2019017938A1 (en) | 2017-07-19 | 2019-01-24 | Amicus Therapeutics, Inc. | TREATMENT OF FABRY'S DISEASE IN PATIENTS WITHOUT SUBSTITUTED ENZYMATIC THERAPY (TES) AND PATIENTS SUBJECT TO TES |
| JP7755929B2 (ja) | 2017-08-28 | 2025-10-17 | アミカス セラピューティックス インコーポレイテッド | ファブリー病患者における心臓機能の強化及び／または安定化方法 |
| CN112203657A (zh) | 2018-02-06 | 2021-01-08 | 阿米库斯治疗学公司 | 患有经典法布里病的患者的治疗 |
| WO2019157047A1 (en) | 2018-02-06 | 2019-08-15 | Amicus Therapeutics, Inc. | Use of migalastat for treating fabry disease in pregnant patients |
| WO2020023390A1 (en) | 2018-07-25 | 2020-01-30 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
| KR20210046729A (ko) | 2018-08-20 | 2021-04-28 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법 |
| NL2021840B1 (en) | 2018-10-19 | 2020-05-13 | Univ Leiden | Pharmacological Chaperones For Enzyme Treatment Therapy |
| WO2020046132A1 (en) | 2018-08-31 | 2020-03-05 | Leiden University | Pharmacological chaperones for enzyme treatment therapy |
| TW202042812A (zh) | 2019-01-22 | 2020-12-01 | 美商阿米庫斯醫療股份有限公司 | 減少法布瑞氏症患者中之腦血管事件之方法 |
| CA3141226A1 (en) | 2019-06-11 | 2020-12-17 | Franklin Johnson | Methods of treating fabry disease in patients having renal impairment |
| US11833164B2 (en) * | 2019-08-07 | 2023-12-05 | Amicus Therapeutics, Inc. | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
| US20230220320A1 (en) | 2019-09-06 | 2023-07-13 | Amicus Therapeutics, Inc. | Method For Capturing And Purification Of Biologics |
| SI4114390T1 (sl) * | 2020-03-06 | 2025-03-31 | Amicus Therapeutics, Inc. | Postopki zdravljenja Fabryjeve bolezni pri bolnikih z mutacijo gena GLA |
| US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
| US20240293387A1 (en) | 2021-07-12 | 2024-09-05 | Amicus Therapeutics, Inc. | Methods of Treating Fabry Disease in Pediatric Patients |
| KR20250007602A (ko) | 2022-05-05 | 2025-01-14 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병 치료에 대한 방법 |
| KR20250110931A (ko) | 2022-12-02 | 2025-07-21 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 소아 환자의 영아-발병 폼페병 치료에 대한 방법 |
| CN121057588A (zh) | 2022-12-02 | 2025-12-02 | 阿米库斯治疗学公司 | 用于在儿科患者中治疗迟发性庞贝病的方法 |
| US20240197706A1 (en) | 2022-12-13 | 2024-06-20 | Amicus Therapeutics, Inc. | Methods of improving the pharmacokinetics of migalastat |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US21381A (en) * | 1858-08-31 | Bracelet | ||
| US203019A (en) * | 1878-04-30 | Improvement in circuits for acoustic or telephonic telegraphs | ||
| US270486A (en) * | 1883-01-09 | Bundle-separating attachment for self-binding harvesters | ||
| US264467A (en) * | 1882-09-19 | Chables h | ||
| US3586908A (en) | 1969-02-28 | 1971-06-22 | Robert E Vosteen | Automatic potential control system for electrophotography apparatus |
| US5401650A (en) * | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| US5863903A (en) | 1994-03-09 | 1999-01-26 | Novo Nordisk A/S | Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes |
| US5844102A (en) | 1994-07-07 | 1998-12-01 | University Of Maryland Baltimore County | Glycohydrolase inhibitors, their preparation and use thereof |
| JP2000509971A (ja) | 1996-04-10 | 2000-08-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 化学的シャペローンを用いる遺伝的欠陥の修正 |
| US6270954B1 (en) | 1996-04-10 | 2001-08-07 | The Regents Of The University Of California | Correction of genetic defects using chemical chaperones |
| US5948653A (en) | 1997-03-21 | 1999-09-07 | Pati; Sushma | Sequence alterations using homologous recombination |
| US6274597B1 (en) * | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| US6244113B1 (en) | 1999-10-29 | 2001-06-12 | University Of Alabama In Huntsville | Method and apparatus for measuring microgravity acceleration |
| US7842470B2 (en) * | 2001-10-09 | 2010-11-30 | Oregon Health & Science University | Method for pharmacoperones correction of GnRHR mutant protein misfolding |
| JP2008545657A (ja) * | 2005-05-17 | 2008-12-18 | アミカス セラピューティックス インコーポレイテッド | １−デオキシノジリマイシンおよび誘導体を用いるポンペ病の治療方法 |
| KR20080033242A (ko) * | 2005-06-08 | 2008-04-16 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 리소좀 효소를 코딩하는 유전자의 돌연변이와 관련있는ｃｎｓ 질환의 치료 방법 |
| WO2008045015A1 (en) | 2005-06-08 | 2008-04-17 | Amicus Therapeutics, Inc. | Imino and amino sugar purification |
| US7790364B2 (en) * | 2006-01-27 | 2010-09-07 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for high throughput screening of pharmacological chaperones |
| CA2652553C (en) | 2006-05-16 | 2020-08-18 | Amicus Therapeutics, Inc. | Use of 1-deoxygalactonojirimycin or a salt thereof in the treatment of fabry disease |
| PL1860101T3 (pl) | 2006-05-24 | 2011-10-31 | Amicus Therapeutics Inc | Sól winianu izofagominy i sposoby zastosowania |
| MX2009011473A (es) | 2007-04-26 | 2010-01-18 | Amicus Therapeutics Inc | Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas. |
| US9999618B2 (en) | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| LT3470077T (lt) | 2008-02-12 | 2021-02-25 | Amicus Therapeutics, Inc. | Atsako į ligų gydymą farmakologiniu šaperonu prognozavimo būdas |
| US8321148B2 (en) | 2008-10-24 | 2012-11-27 | Amicus Therapeutics, Inc. | Multiple compartment dosing model |
| ES2585584T3 (es) | 2009-05-26 | 2016-10-06 | Amicus Therapeutics, Inc. | Utilización de chaperonas farmacológicas para mejorar la fabricación y la purificación de ß-glucosidasa ácida |
| US9206457B2 (en) | 2009-05-26 | 2015-12-08 | Amicus Therapeutics, Inc. | Utilization of pharmacological chaperones to improve manufacturing and purification of biologics |
| JP5739898B2 (ja) | 2009-11-17 | 2015-06-24 | ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ | 心疾患マーカーとしての尿中トリアオシルセラミド（ｇｂ３） |
| CN103974619B (zh) | 2011-03-11 | 2017-02-15 | 阿米库斯治疗学公司 | 治疗法布里病的给药方案 |
| EP2874648A4 (en) | 2012-07-17 | 2015-12-30 | Amicus Therapeutics Inc | CO-FORMULATION OF ALPHA-GALACTOSIDASE A AND 1-DEOXYGALACTONOJIRIMYCIN |
| US10155027B2 (en) | 2012-07-17 | 2018-12-18 | Amicus Therapeutics, Inc. | Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease |
| KR20190087673A (ko) | 2016-03-22 | 2019-07-24 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Ｇｌａ 유전자에 ｇ9331ａ 돌연변이를 갖는 환자에서 파브리 질병의 치료 방법 |
| EP4378524A3 (en) | 2016-07-19 | 2024-08-14 | Amicus Therapeutics, Inc. | Treatment of fabry disease in ert-naive and ert-experienced patients |
| JP2020503900A (ja) | 2017-01-10 | 2020-02-06 | アミカス セラピューティックス インコーポレイテッド | ファブリー病の処置のための組換えアルファ−ガラクトシダーゼａ |
| WO2018222655A1 (en) | 2017-05-30 | 2018-12-06 | Amicus Therapeutics, Inc. | Methods of treating fabry patients having renal impairment |
| WO2019017938A1 (en) | 2017-07-19 | 2019-01-24 | Amicus Therapeutics, Inc. | TREATMENT OF FABRY'S DISEASE IN PATIENTS WITHOUT SUBSTITUTED ENZYMATIC THERAPY (TES) AND PATIENTS SUBJECT TO TES |
| JP7755929B2 (ja) | 2017-08-28 | 2025-10-17 | アミカス セラピューティックス インコーポレイテッド | ファブリー病患者における心臓機能の強化及び／または安定化方法 |
| CN112203657A (zh) | 2018-02-06 | 2021-01-08 | 阿米库斯治疗学公司 | 患有经典法布里病的患者的治疗 |
| WO2019157047A1 (en) | 2018-02-06 | 2019-08-15 | Amicus Therapeutics, Inc. | Use of migalastat for treating fabry disease in pregnant patients |
| KR20210046729A (ko) | 2018-08-20 | 2021-04-28 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법 |
| CA3141226A1 (en) | 2019-06-11 | 2020-12-17 | Franklin Johnson | Methods of treating fabry disease in patients having renal impairment |
| US11833164B2 (en) | 2019-08-07 | 2023-12-05 | Amicus Therapeutics, Inc. | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
-
2009
- 2009-02-12 LT LTEP18201960.4T patent/LT3470077T/lt unknown
- 2009-02-12 DK DK18201960.4T patent/DK3470077T3/da active
- 2009-02-12 LT LTEP15162630.6T patent/LT2946785T/lt unknown
- 2009-02-12 ES ES09710178.6T patent/ES2541933T3/es active Active
- 2009-02-12 HU HUE09710178A patent/HUE026543T2/hu unknown
- 2009-02-12 JP JP2010546901A patent/JP5844045B2/ja active Active
- 2009-02-12 EP EP09710178.6A patent/EP2252313B1/en active Active
- 2009-02-12 WO PCT/US2009/033963 patent/WO2009102895A2/en not_active Ceased
- 2009-02-12 DK DK15162630.6T patent/DK2946785T3/en active
- 2009-02-12 ES ES15162630T patent/ES2716502T3/es active Active
- 2009-02-12 SI SI200932099T patent/SI3470077T1/sl unknown
- 2009-02-12 EP EP15162630.6A patent/EP2946785B1/en active Active
- 2009-02-12 MX MX2010008835A patent/MX2010008835A/es active IP Right Grant
- 2009-02-12 PT PT15162630T patent/PT2946785T/pt unknown
- 2009-02-12 PT PT97101786T patent/PT2252313E/pt unknown
- 2009-02-12 ES ES18201960T patent/ES2836121T3/es active Active
- 2009-02-12 SI SI200931229T patent/SI2252313T1/sl unknown
- 2009-02-12 PL PL18201960T patent/PL3470077T3/pl unknown
- 2009-02-12 HU HUE18201960A patent/HUE051377T2/hu unknown
- 2009-02-12 CA CA2715407A patent/CA2715407C/en active Active
- 2009-02-12 DK DK09710178.6T patent/DK2252313T3/en active
- 2009-02-12 PT PT182019604T patent/PT3470077T/pt unknown
- 2009-02-12 EP EP18201960.4A patent/EP3470077B1/en active Active
- 2009-02-12 HU HUE15162630A patent/HUE042882T2/hu unknown
- 2009-02-12 AU AU2009214648A patent/AU2009214648B2/en active Active
- 2009-02-12 EP EP20192637.5A patent/EP3824900A1/en active Pending
- 2009-02-12 PL PL09710178T patent/PL2252313T3/pl unknown
- 2009-02-12 PL PL15162630T patent/PL2946785T3/pl unknown
- 2009-02-12 HR HRP20150728TT patent/HRP20150728T1/hr unknown
- 2009-02-12 SI SI200931920T patent/SI2946785T1/sl unknown
-
2010
- 2010-08-12 US US12/855,468 patent/US8592362B2/en not_active Ceased
- 2010-08-20 US US12/860,611 patent/US20110152319A1/en not_active Abandoned
-
2013
- 2013-10-15 US US14/054,369 patent/US9095584B2/en active Active
-
2014
- 2014-09-10 AU AU2014221321A patent/AU2014221321B2/en active Active
- 2014-12-02 JP JP2014244283A patent/JP2015091239A/ja active Pending
-
2015
- 2015-06-05 US US14/731,603 patent/US9545397B2/en active Active
- 2015-07-08 CY CY20151100595T patent/CY1116466T1/el unknown
-
2016
- 2016-03-01 JP JP2016039171A patent/JP6672013B2/ja active Active
- 2016-07-20 AU AU2016206297A patent/AU2016206297A1/en not_active Abandoned
- 2016-09-19 US US15/268,662 patent/US20170003301A1/en not_active Abandoned
-
2017
- 2017-11-30 AU AU2017268649A patent/AU2017268649A1/en not_active Abandoned
-
2018
- 2018-07-26 US US16/046,247 patent/US10813921B2/en active Active
- 2018-12-17 US US16/222,305 patent/USRE48608E1/en active Active
- 2018-12-27 JP JP2018245609A patent/JP6837469B2/ja active Active
-
2019
- 2019-01-22 HR HRP20190143TT patent/HRP20190143T1/hr unknown
- 2019-01-24 CY CY20191100100T patent/CY1121386T1/el unknown
- 2019-08-20 AU AU2019219727A patent/AU2019219727B2/en active Active
-
2020
- 2020-10-26 US US17/079,859 patent/US20250082621A9/en active Pending
- 2020-11-17 HR HRP20201827TT patent/HRP20201827T1/hr unknown
- 2020-11-25 CY CY20201101114T patent/CY1123816T1/el unknown
-
2021
- 2021-02-09 JP JP2021019383A patent/JP7277493B2/ja active Active
- 2021-08-20 AU AU2021218172A patent/AU2021218172A1/en not_active Abandoned
-
2023
- 2023-05-08 JP JP2023076515A patent/JP2023109807A/ja not_active Withdrawn
-
2024
- 2024-09-24 AU AU2024219997A patent/AU2024219997A1/en active Pending
-
2025
- 2025-06-11 JP JP2025097940A patent/JP2025148351A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016163571A5 (enExample) | ||
| MX2021002322A (es) | Nuevos metodos. | |
| JP2017506624A5 (enExample) | ||
| JP2016147915A5 (enExample) | ||
| FI3504187T3 (fi) | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten | |
| JP2009280621A5 (enExample) | ||
| JP2016106150A5 (enExample) | ||
| EA200800881A1 (ru) | Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами | |
| JP2017057230A5 (enExample) | ||
| JP2018184462A5 (enExample) | ||
| JP2017528507A5 (enExample) | ||
| FI3457135T3 (fi) | Fabryn taudin hoitovaihtoehtoja | |
| JP2017075173A5 (enExample) | ||
| WO2020115555A3 (en) | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia | |
| RU2017114352A (ru) | АНТАГОНИСТЫ ИНТЕГРИНА ανβ6 | |
| FI3840753T3 (fi) | Migalastaatti käytettäväksi fabryn taudin hoitomenetelmissä potilailla joilla on gla-geenin mutaatio | |
| PH12020551911A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| JP2020529995A5 (enExample) | ||
| JP2020536085A5 (enExample) | ||
| RU2018136580A (ru) | Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты | |
| PE20191240A1 (es) | Formas de administracion farmaceutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios | |
| MX2024007642A (es) | Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades. | |
| MX2016008027A (es) | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. | |
| FI2608789T4 (fi) | 1-[2-(2,4-dimetyyli-fenyylisulfanyyli)fenyyli]piperatsiinin terapeuttisia käyttötapoja | |
| JP2016523943A5 (enExample) |